This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
EXPLORE/HORIZON
Gene Therapy Study to Evaluate the Safety and Efficacy of GT005 in people with Geographic Atrophy Secondary to Age-Related Macular Degeneration. This study is operated by the Centre for Eye Research Australia.
Overview
This Phase II clinical study is exploring the safety and efficacy of two doses of GT005 administered as a single subretinal injection in people with geographic atrophy secondary to age-related macular degeneration.
Participants are randomised into either a treated or no treatment/control group and will be followed up for 2 years.
- Principal Investigator
Dr Thomas Edwards
This Phase II clinical study is exploring the safety and efficacy of two doses of GT005 administered as a single subretinal injection in people with geographic atrophy secondary to age-related macular degeneration.
Participants are randomised into either a treated or no treatment/control group and will be followed up for 2 years.
- Principal Investigator